Propanc Biopharma (PPCB) vs XTL Biopharmaceuticals (XTLB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
XTL Biopharmaceuticals is the larger company by market cap ($4.9 million vs $4.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PPCB | XTLB |
|---|---|---|
| Share price | $0.471 | $1.99 |
| Market cap | $4.63M | $4.89M |
| 1-day change | -5.55% | +0.51% |
| EPS (TTM) | $-17.62 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $48.75 | $6.48 |
| 52-week low | $0.46 | $1.97 |
| Distance from 52-week high | -99.03% | -69.29% |
| Average volume | 1.79M | 8.62K |
| Shares outstanding | 9.83M | 2.46M |
| Employees | 2 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Propanc Biopharma
PPCB stock →Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About XTL Biopharmaceuticals
XTLB stock →XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
PPCB vs XTLB FAQ
Which is bigger, Propanc Biopharma or XTL Biopharmaceuticals?
XTL Biopharmaceuticals (XTLB) is larger, with a market capitalization of $4.89M compared with $4.63M for Propanc Biopharma (PPCB).
Are Propanc Biopharma and XTL Biopharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.